Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Axsome Therapeutics Inc shares valued at $768,525 were sold by Murdock Hunter R. on Jun 20 ’25. At $102.47 per share, Murdock Hunter R. sold 7,500 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
Also, Murdock Hunter R. sold 6,014 shares, netting a total of over 602,122 in proceeds. Following the sale of shares at $100.12 each, the insider now holds 0 shares.
Before that, Murdock Hunter R. had added 6,014 shares to its account. In a trade valued at $602,101, the Officer bought Axsome Therapeutics Inc shares for $100.12 each.
Analysts at Oppenheimer started covering the stock with ‘”an Outperform”‘ outlook in a report released in early June. As of April 07, 2025, Jefferies has initiated its “Buy” rating for AXSM. Earlier on February 11, 2025, Deutsche Bank initiated its rating. Their recommendation was “a Buy” for AXSM stock.
Analyzing AXSM Stock Performance
On last trading session,, Axsome Therapeutics Inc [NASDAQ: AXSM] rose 0.83% to $112.24. The stock’s lowest price that day was $110.76, but it reached a high of $113.5 in the same session. During the last five days, there has been a surge of approximately 1.36%. Over the course of the year, Axsome Therapeutics Inc shares have jumped approximately 35.56%.
Support And Resistance Levels for Axsome Therapeutics Inc (AXSM)
RSI (Relative Strength Index) is 60.26 on the 14-day chart, showing neutral technical sentiment.
Is Axsome Therapeutics Inc subject to short interest?
Stocks of Axsome Therapeutics Inc saw a sharp rise in short interest on 2025-06-13 jumping by 0.13 million shares to 4.02 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 3.89 million shares. A jump of 3.28% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.45 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.45.
Which companies own the most shares of Axsome Therapeutics Inc (AXSM)?
In terms of Axsome Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 190 in the next 12 months, up nearly 70.68% from the previous closing price of $111.32. Analysts anticipate Axsome Therapeutics Inc stock to reach 216 by 2025, with the lowest price target being 162. In spite of this, 15 analysts ranked Axsome Therapeutics Inc stock as Buy at the end of 2025. On December 31, 2024, Mizuho assigned a price target of “an Outperform” to the stock and reiterated coverage with a $122.
